Markets
Insight Molecular Diagnostics Inc. (IMDX)
IMDXNASDAQ-CMBiotechnology: In Vitro & In Vivo Diagnostic Substances
$2.50
0.0000 (0.00%) today
Pre-market, Nov 9, 4:00 PM ET
+1.63% 1D
- Market cap
- $81.81m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.35 to $8.51
- Average volume
- 240.3k
- Previous close
- $2.50
Analysts
4 coveringHold3 buy, 1 hold, 0 sell
Targets a year out average $9.67, +286.8% from here
$8.00now $2.50$12.00
Earnings
Next report Nov 16, 2026
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $260.0k | $1.14m | $32.0k | $239.0k |
| Gross profit | $139.0k | $496.0k | $15.0k | $157.0k |
| Operating income | -$11.05m | -$23.43m | -$4.41m | -$11.40m |
| Net income | -$10.85m | -$22.95m | -$4.29m | -$11.26m |
Last four quarters: revenue $1.67m, margin -2955.6%, free cash flow -$31.00m
News
8 latest- Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 17, 2026
- Oncocyte Eyes Faster, Less Invasive Heart Transplant Rejection TestingMarketBeat · Aug 17, 2026
- Oncocyte Q2 Earnings Call HighlightsMarketBeat · Aug 10, 2026
- IMDX Q1 2026 Earnings Call TranscriptThe Motley Fool · May 13, 2026
- Monday Sector Leaders: Biotechnology, Oil & Gas Refining & Marketing StocksBNK Invest · May 4, 2026
- Tuesday Sector Leaders: Biotechnology, Medical Instruments & SuppliesBNK Invest · Apr 14, 2026
- Insight Molecular Diagnostics (IMDX) Price Target Increased by 19.05% to 8.50Fintel · Feb 24, 2026
- Insight Molecular Diagnostics (IMDX) Price Target Increased by 29.23% to 7.14Fintel · Nov 16, 2025
The company
Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- imdxinc.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.